Intracerebroventricular injection of a neuropeptide Y-Y1 receptor agonist increases while BIBP3226, a Y1 antagonist, reduces the infarct volume following transient middle cerebral artery occlusion in rats

Neuroscience

Volumn 116, Issue 1, 2003, Pages 119-126

  Chen, S H ^a   Cheung, R T F ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

2,3,5 triphenyltetrazolium chloride; Neuropeptide Y receptor; Neuroprotection; Stroke; Stroke model

Indexed keywords

CALCIUM; GLUTAMIC ACID; NALPHA (DIPHENYLACETYL) N (4 HYDROXYBENZYL) DEXTRO ARGININAMIDE; NEUROPEPTIDE Y RECEPTOR AGONIST; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; NEUROPEPTIDE Y [31 LEUCINE 34 PROLINE]; NEUROPEPTIDE Y[3-36]; NITRIC OXIDE; TRIPHENYLTETRAZOLIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MONITORING; BRAIN INFARCTION; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; BRAIN PERFUSION; BRAIN SLICE; CONTROLLED STUDY; DRUG EFFECT; HEART RATE; HEMODYNAMICS; INHIBITION KINETICS; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION;

EID: 0037439157     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(02)00576-6     Document Type: Article

References (53)

1. Aakerlund L., Gether U., Fuhlendorff J., Schwartz T.W., Thastrup O. Y1 receptors for neuropeptide Y are coupled to mobilization of intracellular calcium and inhibition of adenylate cyclase. FEBS Lett. 260:1990;73-78.
2. Abel P.W., Han C. Effects of neuropeptide Y on contraction, relaxation, and membrane potential of rabbit cerebral arteries. J Cardiovasc Pharmacol. 13:1989;52-63.
3. Abounader R., Villemure J.G., Hamel E. Characterization of neuropeptide Y (NPY) receptors in human cerebral arteries with selective agonists and the new Y1 antagonist BIBP 3226. Br J Pharmacol. 116:1995;2245-2250.
4. Allen J.M., Schon F., Todd N., Yeats J.C., Crockard H.A., Bloom S.R. Presence of neuropeptide Y in human circle of Willis and its possible role in cerebral vasospasm. Lancet. 2:1984;550-552.
5. Allen G.V., Cheung R.T., Cechetto D.F. Neurochemical changes following occlusion of the middle cerebral artery in rats. Neuroscience. 68:1995;1037-1050.
6. Bard J.A., Walker M.W., Branchek T.A., Weinshank R.L. Cloning and functional expression of a human Y4 subtype receptor for pancreatic polypeptide, neuropeptide Y, and peptide YY. J Biol Chem. 270:1995;26762-26765.
7. Bitran M., Tapia W., Eugenin E., Orio P., Boric M.P. Neuropeptide Y induced inhibition of noradrenaline release in rat hypothalamus role of receptor subtype and nitric oxide. Brain Res. 851:1999;87-93.
8. Blomqvist A.G., Herzog H. Y-receptor subtypes how many more? Trends Neurosci. 20:1997;294-298.
9. Chen S.H., Cheung R.T. Peripheral and central administration of neuropeptide Y in a rat middle cerebral artery occlusion stroke model reduces cerebral blood flow and increases infarct volume. Brain Res. 927:2002;138-143.
10. Chen S.H., Fung P.C., Cheung R.T. Neuropeptide Y-Y1 receptor modulates nitric oxide level during stroke in the rat. Free Radical Bio Med. 2002;. 32:776-784.
11. Cheung R.T., Cechetto D.F. Neuropeptide changes following excitotoxic lesion of the insular cortex in rats. J Comp Neurol. 362:1995;535-550.
12. Cheung R.T., Cechetto D.F. Colchicine affects cortical and amygdalar neurochemical changes differentially after middle cerebral artery occlusion in rats. J Comp Neurol. 387:1997;27-41.
13. Cheung R.T., Cechetto D.F. Neuropeptide Y-Y1 receptor antisense oligodeoxynucleotide increases the infarct volume after middle cerebral artery occlusion in rats. Neuroscience. 98:2000;771-777.
14. Cheung R.T., Diab T., Cechetto D.F. Time-course of neuropeptide changes in peri-ischemic zone and amygdala following focal ischemia in rats. J Comp Neurol. 360:1995;101-120.
15. Cheung R.T., Hachinski V.C., Cechetto D.F. Cardiovascular response to stress after middle cerebral artery occlusion in rats. Brain Res. 747:1997;181-188.
16. Doods H.N., Wienen W., Entzeroth M., Rudolf K., Eberlein W., Engel W., Wieland H.A. Pharmacological characterization of the selective nonpeptide neuropeptide Y Y1 receptor antagonist BIBP 3226. J Pharmacol Exp Ther. 275:1995;136-142.
17. Dumont Y., Fournier A., Quirion R. Expression and characterization of the neuropeptide Y Y5 receptor subtype in the rat brain. J Neurosci. 18:1998;5565-5574.
18. Edvinsson L., Emson P., McCulloch J., Tatemoto K., Uddman R. Neuropeptide Y immunocytochemical localization to and effect upon feline pial arteries and veins in vitro and in situ. Acta Physiol Scand. 122:1984;155-163.
19. Elias C.F., Aschkenasi C., Lee C., Kelly J., Ahima R.S., Bjorbaek C., Flier J.S., Saper C.B., Elmquist J.K. Leptin differentially regulates NPY and POMC neurons projecting to the lateral hypothalamic area. Neuron. 23:1999;775-786.
20. 3H] BIBP3226. Eur J Pharmacol. 278:1995;239-242.
21. Everitt B.J., Hokfelt T., Terenius L., Tatemoto K., Mutt V., Goldstein M. Differential co-existence of neuropeptide Y (NPY)-like immunoreactivity with catecholamines in the central nervous system of the rat. Neuroscience. 11:1984;443-462.
22. Figueredo-Cardenas G., Morello M., Sancesario G., Bernardi G., Reiner A. Colocalization of somatostatin, neuropeptide Y, neuronal nitric oxide synthase and NADPH-diaphorase in striatal interneurons in rats. Brain Res. 735:1996;317-324.
23. Figueredo-Cardenas G., Harris C.L., Anderson K.D., Reiner A. Relative resistance of striatal neurons containing calbindin or parvalbumin to quinolinic acid-mediated excitotoxicity compared to other striatal neuron types. Exp Neurol. 149:1998;356-372.
24. Franco-Cereceda A., Liska J. Neuropeptide Y Y1 receptors in vascular pharmacology. Eur J Pharmacol. 349:1998;1-14.
25. 34]-neuropeptide Y a specific Y1 receptor agonist. Proc Natl Acad Sci USA. 87:1990;182-186.
26. Grandt D., Schimiczek M., Rascher W., Feth F., Shively J., Lee T.D., Davis M.T., Reeve J.R.J.r, Michel M.C. Neuropeptide Y 3-36 is an endogenous ligand selective for Y2 receptors. Regul Pept. 67:1996;33-37.
27. Gregor P., Feng Y., DeCarr L.B., Cornfield L.J., McCaleb M.L. Molecular characterization of a second mouse pancreatic polypeptide receptor and its inactivated human homologue. J Biol Chem. 271:1996;27776-27781.
28. Grimaldi R., Zini I., Biagini G., Toffano G., Agnati L.F. Effects of centrally administered clonidine and neuropeptide Y on arterial blood pressure in the rat after transient forebrain ischemia. J Auton Nerv Syst. 30:1990;S67-S69.
29. von Horsten S., Ballof J., Helfritz F., Nave H., Meyer D., Schmidt R.E., Stalp M., Klemm A., Tschernig T., Pabst R. Modulation of innate immune functions by intracerebroventricularly applied neuropeptide Y dose and time dependent effects. Life Sci. 63:1998;909-922.
30. Hu Y., Dunbar J.C. Regional vascular and cardiac responses to systemic neuropeptide-Y in normal and diabetic rats. Peptides. 18:1997;809-815.
31. Hu Y., Dunbar J.C. Intracerebroventricular administration of NPY increases sympathetic tone selectively in vascular beds. Brain Res Bull. 44:1997;97-103.
32. Isayama K., Pitts L.H., Nishimura M.C. Evaluation of 2,3,5-triphenyltetrazolium chloride staining to delineate rat brain infarcts. Stroke. 22:1991;1394-1398.
33. Longa E.Z., Weinstein P.R., Carlson S., Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 20:1989;84-91.
34. Lundberg J.M., Modin A. Inhibition of sympathetic vasoconstriction in pigs in vivo by the neuropeptide Y-Y1 receptor antagonist BIBP 3226. Br J Pharmacol. 116:1995;2971-2982.
35. Lundell I., Blomqvist A.G., Berglund M.M., Schober D.A., Johnson D., Statnick M.A., Gadski R.A., Gehlert D.R., Larhammar D. Cloning of a human receptor of the NPY receptor family with high affinity for pancreatic polypeptide and peptide YY. J Biol Chem. 270:1995;29123-29128.
36. Matsui T., Nagafuji T., Kumanishi T., Asano T. Role of nitric oxide in pathogenesis underlying ischemic cerebral damage. Cell Mol Neurobiol. 19:1999;177-189.
37. Michel M.C., Beck-Sickinger A., Cox H., Doods H.N., Herzog H., Larhammar D., Quirion R., Schwartz T., Westfall T. XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol Rev. 50:1998;143-150.
38. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1998;Academic Press, San Diego.
39. Pei Z., Ho H.T., Cheung R.T.F. Pre-treatment with melatonin reduces volume of cerebral infarction in a permanent middle cerebral artery occlusion stroke model in the rat. Neurosci Lett. 318:2002;141-144.
40. Petty M.A., Dietrich R., Lang R.E. The cardiovascular effects of neuropeptide Y (NPY). Clin Exp Hypertens. 6:1984;1889-1892.
41. Pulsinelli W. Pathophysiology of acute ischaemic stroke. Lancet. 339:1992;533-536.
42. Rudolf K., Eberlein W., Engel W., Wieland H.A., Willim K.D., Entzeroth M., Wienen W., Beck-Sickinger A.G., Doods H.N. The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist BIBP3226. Eur J Pharmacol. 271:1994;R11-R13.
43. Schaffhauser A.O., Whitebread S., Haener R., Hofbauer K.G., Stricker-Krongrad A. Neuropeptide Y Y1 receptor antisense oligodeoxynucleotides enhance food intake in energy-deprived rats. Reg Peptides. 75-76:1998;417-423.
44. Scott N.A., Webb V., Boublik J.H., Rivier J., Brown M.R. The cardiovascular actions of centrally administered neuropeptide Y. Reg Peptides. 25:1989;247-258.
45. Stoddard S.L., Tyce G.M., Ahlskog J.E., Zinsmeister A.R., Nelson D.K., Carmichael S.W. Decreased levels of [Met] enkephalin, neuropeptide Y, substance P, and vasoactive intestinal peptide in parkinsonian adrenal medulla. Exp Neurol. 114:1991;23-27.
46. Suzuki Y., Shibuya M., Ikegaki I., Satoh S., Takayasu M., Asano T. Effects of neuropeptide Y on canine cerebral circulation. Eur J Pharmacol. 146:1988;271-277.
47. Suzuki Y., Satoh S., Ikegaki I., Okada T., Shibuya M., Sugita K., Asano T. Effects of neuropeptide Y and calcitonin gene-related peptide on local cerebral blood flow in rat striatum. J Cereb Blood Flow Metab. 9:1989;268-270.
48. Tanaka K. Alteration of second messengers during acute cerebral ischemia adenylate cyclase, cyclic AMP-dependent protein kinase, and cyclic AMP response element binding protein. Prog Neurobiol. 65:2001;173-207.
49. Tatemoto K. Neuropeptide Y complete amino acid sequence of the brain peptide. Proc Natl Acad Sci USA. 79:1982;5485-5489.
50. Vanderheyden P.M., van Liefde I., de Backer J.P., Vauquelin G. Non-competitive binding of the nonpeptide antagonist BIBP3226 to rat forebrain neuropeptide Y1 receptors. Eur J Pharmacol. 331:1997;275-284.
51. Wahlestedt C., Reis D.J. Neuropeptide Y-related peptides and their receptors are the receptors potential therapeutic drug targets? Annu Rev Pharmacol Toxicol. 33:1993;309-352.
52. Wahlestedt C., Pich E.M., Koob G.F., Yee F., Heilig M. Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides. Science. 259:1993;528-531.
53. Weng G., Feinstein D., Reis D., Wahlestedt C. Neuropeptide Y receptor gene regulation in mouse adrenocortical Y-1 cells. Reg Peptides. 63:1996;53-56.